Medical Research Organizations
Israel Cancer Research Fund
The Israel Cancer Research Fund (ICRF) supports groundbreaking cancer research by outstanding scientists in Israel. It is a voluntary charitable organization funded exclusively by private donations. Israeli researchers have been at the forefront of many of this decade’s most exciting developments in cancer research. In 2004, two ICRF-funded scientists won the Nobel Prize in Chemistry.
The Faas Foundation is a proud supporter of ICRF and is currently funding two professorships over 7 years. A named Professorship is awarded to senior faculty or persons in equivalent positions who have made outstanding contributions to cancer research. The following scientists are currently being funded by The Faas Foundation.
ALBERTO GABIZON, M.D., PH.D. AT SHAARE ZEDEK MEDICAL CENTRE
Dr. Gabizon’s project is titled “Development of Targeted Liposome Formulations of Anti-Cancer Agents.” His work has resulted in the targeted cancer treating drug, Doxil. Doxil is currently used in treating several forms of cancer, including breast cancer. Approximately 100,000 people worldwide are on this drug. Dr. Gabizon’s current work is to continue in this research to formulate drugs that can interact with our body in a smarter and more effective way.
ISRAEL VLODAVSKY, PH.D. AT TECHNION, ISRAEL INSTITUTE OF TECHNOLOGY
Dr. Vladovsky’s project is titled “Targeting Heparanase, One Molecule with Multiple Functions in Human Cancer Progression.” Dr. Vladovsky’s research over the past couple of years has led to a better understanding of the mode of action and involvement of Heparanase in cancer progression and the associated prognostic and therapeutic applications. Heparanase is an enzyme first identified and characterized in Vladavsky’s laboratory.